ReviewAnnals of translational medicine2020
Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches.
Review in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Female fertility preservation: 25 years of progress, expanding indications and future prospects.Human reproduction update · 2026Review
- Individualized survival prediction and risk stratification using machine learning for patients with malignant struma ovarii: a population-based study with external validation.Gland surgery · 2025Article
- Article
- Acute abdominopelvic pain and distension in a 21-year-old woman revealing a mixed germ cell tumor: A case report.International journal of surgery case reports · 2025Article
- Revitalizing premature ovarian failure: quercetin counteracts imatinib-induced apoptosis via the PI3K/AKT signaling pathway based on network pharmacology.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.Frontiers in cell and developmental biology · 2025Review
- Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.Cureus · 2024Review
- Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours.International journal of environmental research and public health · 2023Review
- Fertility and prognosis assessment between bleomycin/etoposide/cisplatin and paclitaxel/carboplatin chemotherapy regimens in the conservative treatment of malignant ovarian germ cell tumors: a multicenter and retrospective study.Journal of gynecologic oncology · 2023Article
- A Rare Case of Granulosa Cell Tumor Associated With Endometrial Carcinoma - A Case Report.Cureus · 2022Article
- Efficacy and Safety of Platinum-Based Chemotherapy for Ovarian Cancer During Pregnancy: A Systematic Review and Meta-Analysis.Oncology and therapy · 2022Review
- Incidence and Survival Rates for Female Malignant Germ Cell Tumors: An Institutional Review.Cureus · 2022Article
- Non-Epithelial Ovarian Cancers: How Much Do We Really Know?International journal of environmental research and public health · 2022Review
- Successful treatment of a patient with renal failure, treated with haemodialysis, and advanced ovarian germ cell tumour using modified cisplatin-based chemotherapy duplet.Ecancermedicalscience · 2022Article
- Oncological and Reproductive Outcomes in Patients With Advanced-Stage Ovarian Immature Teratoma: Experience From a Tertiary Center.Frontiers in oncology · 2022Article
- Female Germ Cell Development, Functioning and Associated Adversities under Unfavorable Circumstances.International journal of molecular sciences · 2021Review
- Wise Management of Ovarian Cancer: On the Cutting Edge.Journal of personalized medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant ovarian germ cell tumours (MOGCTs) are rare. Unlike epithelial ovarian cancer, MOGCTs typically occur in girls and young women. Fertility-sparing surgery and platinum-based chemotherapy remain the standard of care, providing high chance of cure at all stages. Given the lack of high-quality studies in this field, current practice guidelines recommend chemotherapy regimens adopted in testicular germ cell tumours. However, platinum-resistant/refractory MOGCTs retain a worse prognosis in comparison with their male counterpart. Herein, we focus on current systemic anti-cancer treatment options in MOGCTs and promising approaches. Future studies enrolling exclusively female participants or germ cell tumour trials allowing participation of MOGCT patients are strongly recommended in order to improve evidence on existing management and develop novel strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.